Concurrent targeting of BMI1 and CDK4/6 abrogates tumor growth in vitro and in vivo

Despite recent advances in cancer management and therapy, resistance to cytotoxic medications remains a major clinical challenge; hence, combination-based anti-cancer treatment regimens are currently gaining momentum. PTC-209 reduced BMI1 protein expression, while palbociclib inhibited CDK4, Rb, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Elango, Ramesh, Vishnubalaji, Radhakrishnan, Manikandan, Muthurangan, Binhamdan, Sarah Ibrahim, Siyal, Abdul-Aziz, Alshawakir, Yasser A., Alfayez, Musaad, Aldahmash, Abdullah, Alajez, Nehad M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6757061/
https://www.ncbi.nlm.nih.gov/pubmed/31548560
http://dx.doi.org/10.1038/s41598-019-50140-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6757061/
https://www.ncbi.nlm.nih.gov/pubmed/31548560
http://dx.doi.org/10.1038/s41598-019-50140-0

Ejemplares similares